ARTICLE | Clinical News
Sotrastaurin: Development discontinued
April 30, 2012 7:00 AM UTC
Novartis disclosed in its 1Q12 earnings that it discontinued development of sotrastaurin to prevent kidney and liver transplant rejection and to treat psoriasis after a review of Phase II data showed ...